Stock Price & Analysis

Based on the analysis of BioMarin Pharmaceutical Inc. (BMRN), the stock presents a Hold recommendation. The company has shown strong financial performance, with robust growth in Voxzogo sales and a solid pipeline, but faces competitive threats and valuation concerns.

BMRN stock is predicted to reach $85 - $95 in 2025, driven by strong Q4 earnings, positive analyst upgrades, and growing pipeline potential. The stock's current momentum and long-term outlook suggest continued growth.

The S1 support level for BMRN Stock is $69.01 ,The R1 resistant level for BMRN Stock is $72.9.

As of the end of day on 2025-03-17, the price of BMRN Stock was $69.71.

The target price for BMRN Stock according to analyst rating is 99.00, with the highest price target at 127.00 and the lowest at 70.00. Analysts have a Strong Buy rating on BMRN Stock overall.

The market cap of BMRN is $13.2B.

Analysis and Insights

Valuation Metrics

BMRN's current valuation metrics suggest a premium relative to industry averages:

• PE Ratio: 81.83 (high compared to biotech industry average).
• EV/EBITDA: 53.67 (elevated, indicating high expectations for future growth).
• PS Ratio: 6.84 (above industry norms, signaling rich valuation).
• PB Ratio: 3.27 (moderate but still reflective of investor confidence).

Revenue and Profitability

BMRN has shown consistent revenue growth, with Q4 2024 revenue reaching $747.31 million, up 15% year-over-year. Net income has also improved, reflecting strong margins and operational efficiency.

Analyst Sentiment

Analysts are broadly positive, with a consensus Buy/Outperform rating and price targets ranging from $70 to $126. Recent upgrades highlight confidence in BMRN's pipeline and commercial execution.

Financial Health

• Debt-to-Equity Ratio: 21.44% (manageable).
• Current Ratio: 2.74 (healthy liquidity).
• ROE: 16.72% (solid returns on equity).

Conclusion

While BMRN's valuation multiples appear stretched, its strong revenue growth, expanding margins, and positive analyst sentiment justify its current price. The stock is fairly valued given its growth prospects.

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

BioMarin Pharmaceutical Inc. (BMRN) is expected to reach a stock price of $120 by 2030, driven by its strong financial performance, including revenue growth and positive earnings surprises. The company's focus on rare disease treatments and pipeline expansion, such as Voxzogo, supports this bullish outlook. Analyst upgrades and a price target of $98 further indicate confidence in its long-term growth potential.

BMRN has a total of 3401 employees.